Zalmoxis Európska únia - slovenčina - EMA (European Medicines Agency)

zalmoxis

molmed spa - alogénnou t bunky geneticky zmenené s antiretrovírusovej vektor kódovanie pre skrátená forma ľudskej nízkou afinitou receptorov nervového rastového faktora (Δlngfr) a herpes simplex vírus tymidínovej kinázy (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastické činidlá - zalmoxis je indikovaný ako prídavná liečba v haploidentical transplantácii hematopoetických kmeňových buniek (hsct) u dospelých pacientov s vysokým rizikom hematologických malignít.

Cystadane Európska únia - slovenčina - EMA (European Medicines Agency)

cystadane

recordati rare diseases - betaine bezvodý - homocystinúria - iné alimentárny trakt a metabolizmus výrobky, - adjunctive treatment of homocystinuria, involving deficiencies or defects in:cystathionine beta-synthase (cbs);5,10-methylene-tetrahydrofolate reductase (mthfr);cobalamin cofactor metabolism (cbl). cystadane should be used as supplement to other therapies such as vitamin b6 (pyridoxine), vitamin b12 (cobalamin), folate and a specific diet.

Focetria Európska únia - slovenčina - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - chrípkové vakcíny - profylaxia chrípky spôsobená vírusom a (h1n1v) 2009. focetria by mali byť použité v súlade s oficiálne usmernenie.

Zabdeno Európska únia - slovenčina - EMA (European Medicines Agency)

zabdeno

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemorrhagic fever, ebola - vakcíny - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Breyanzi Európska únia - slovenčina - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastické činidlá - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Esbriet Európska únia - slovenčina - EMA (European Medicines Agency)

esbriet

roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresíva - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.

Isturisa Európska únia - slovenčina - EMA (European Medicines Agency)

isturisa

recordati rare diseases - osilodrostat fosfát - cushingov syndróm - kortikosteroidy na systémové použitie - isturisa je indikovaný na liečbu endogénnych cushing syndróm u dospelých.

Pirfenidone Viatris Európska únia - slovenčina - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresíva - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Adcetris Európska únia - slovenčina - EMA (European Medicines Agency)

adcetris

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastické činidlá - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris je indikovaný na liečbu dospelých pacientov s relapsed alebo žiaruvzdorné cd30+ hodgkinovým lymfómom (hl):v nadväznosti na asct, orfollowing aspoň dve predchádzajúce terapie pri asct alebo multi-agent chemoterapia nie je možnosť liečby. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.